Trial intelligence / Profile preview

Dasatinib for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

ChiCTR1800015763Phase 4Recruiting

Sponsor
West China Hospital of Sichuan University
Start
Jan 2016
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of dasatinib in acute lymphoblastic leukemia (ALL), sponsored by West China Hospital of Sichuan University. Primary endpoints: Complete remission rate, Overall survival and 1 more. Started Jan 2016; status: recruiting.

02

Drugs

dasatinib
03

Conditions

acute lymphoblastic leukemia (ALL)

Beyond the preview

Go deeper on ChiCTR1800015763.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR1800015763.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call